Genetically targeted technologies can improve heart disease treatment, but only with legislation that supports continued research and development.

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients ...

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

When pregnant patients and their families receive a prenatal diagnosis of a congenital heart defect (CHD), it sparks ...

Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...

Discover how the experimental drug lepodisiran dramatically lowers lipoprotein(a) levels, potentially transforming treatment ...

“A major shift is needed from acute event-centred care to strategies focused on early diagnosis, prevention, and management ...

Edwards Lifesciences (NYSE:EW) recently announced significant findings at the ACC Annual Scientific Session, showcasing crucial research in the treatment of structural heart disease. This development, ...

Did you know men and women's heart cells prefer different kinds of fuel? Gender differences are emerging as scientists turn ...

The Government's recently launched AI Action Plan, focusing on creating a National Data Library, marks a pivotal moment for ...

Eli Lilly's lepodisiran met Phase 2 trial goals, significantly lowering Lp(a) levels. A Phase 3 study is enrolling to assess ...